• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

Polymyalgia rheumatica and giant cell arteritis.

作者信息

Cimmino M A, Salvarani C

机构信息

Dipartimento di Medicina Interna, University of Genova School of Medicine, Italy.

出版信息

Baillieres Clin Rheumatol. 1995 Aug;9(3):515-27. doi: 10.1016/s0950-3579(05)80256-0.

DOI:10.1016/s0950-3579(05)80256-0
PMID:7497536
Abstract

The original descriptions of polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) in the medical literature date back to 1888 and 1890, respectively. Classification criteria for PMR and GCA are not standardized since most authors used subjective criteria based on their personal experience. Only one study has evaluated criteria for PMR and has found seven variables with high discriminant value. Criteria for GCA are less varied because a positive biopsy of the temporal artery is diagnostic. However, combinations of different clinical and laboratory features have been used for diagnosis when biopsy is negative or missing. Assessment of PMR/GCA is based on the serial determination of markers of acute phase such as ESR, CRP, or plasma viscosity. However, their value in predicting recurrence of the diseases is poor. New immunological factors including soluble interleukin-2 receptors, interleukin-6, serum soluble CD8, and serum soluble intercellular adhesion molecule-1 are presently under investigation.

摘要

相似文献

1
Polymyalgia rheumatica and giant cell arteritis.
Baillieres Clin Rheumatol. 1995 Aug;9(3):515-27. doi: 10.1016/s0950-3579(05)80256-0.
2
Laboratory investigations including liver in polymyalgia rheumatica/giant cell arteritis.
Baillieres Clin Rheumatol. 1991 Dec;5(3):475-84. doi: 10.1016/s0950-3579(05)80066-4.
3
Polymyalgia rheumatica in biopsy proven giant cell arteritis does not constitute a different subset but differs from isolated polymyalgia rheumatica.活检证实为巨细胞动脉炎的风湿性多肌痛并不构成一个不同的亚组,而是与孤立性风湿性多肌痛有所不同。
J Rheumatol. 1998 Sep;25(9):1750-5.
4
Small-vessel vasculitis surrounding an uninflamed temporal artery: a new diagnostic criterion for polymyalgia rheumatica?未发炎颞动脉周围的小血管炎:多肌痛风湿的一项新诊断标准?
Arthritis Rheum. 2008 Aug;58(8):2565-73. doi: 10.1002/art.23700.
5
Circulating CD8+ T cells in polymyalgia rheumatica and giant cell arteritis: a review.风湿性多肌痛和巨细胞动脉炎中的循环CD8 + T细胞:综述
Semin Arthritis Rheum. 2001 Feb;30(4):257-71. doi: 10.1053/sarh.2001.9734.
6
Classification/diagnostic criteria for GCA/PMR.巨细胞动脉炎/多发性肌炎的分类/诊断标准。
Clin Exp Rheumatol. 2000 Jul-Aug;18(4 Suppl 20):S4-5.
7
Laboratory investigations useful in the evaluation of polymyalgia rheumatica (PMR) and giant cell arteritis (GCA).有助于评估风湿性多肌痛(PMR)和巨细胞动脉炎(GCA)的实验室检查。
Clin Exp Rheumatol. 2000 Jul-Aug;18(4 Suppl 20):S29-31.
8
Management of difficult polymyalgia rheumatica and giant cell arteritis: Updates for clinical practice.治疗困难型巨细胞动脉炎和风湿性多肌痛:临床实践更新。
Best Pract Res Clin Rheumatol. 2018 Dec;32(6):803-812. doi: 10.1016/j.berh.2019.04.006. Epub 2019 May 23.
9
Serum markers associated with disease activity in giant cell arteritis and polymyalgia rheumatica.巨细胞动脉炎和风湿性多肌痛与疾病活动相关的血清标志物。
Rheumatology (Oxford). 2015 Aug;54(8):1397-402. doi: 10.1093/rheumatology/keu526. Epub 2015 Feb 26.
10
[Giant cell arteritis and polymyalgia rheumatica: diagnostic criteria].[巨细胞动脉炎和风湿性多肌痛:诊断标准]
Rev Med Interne. 2013 Jul;34(7):403-11. doi: 10.1016/j.revmed.2013.02.025. Epub 2013 Mar 15.

引用本文的文献

1
The correct prednisone starting dose in polymyalgia rheumatica is related to body weight but not to disease severity.在风湿性多肌痛中,正确的泼尼松起始剂量与体重有关,但与疾病严重程度无关。
BMC Musculoskelet Disord. 2011 May 14;12(1):94. doi: 10.1186/1471-2474-12-94.
2
[Giant cell arteritis: the story].[巨细胞动脉炎:故事]
Z Rheumatol. 2006 Feb;65(1):54, 56-61. doi: 10.1007/s00393-005-0003-6.